PGR and breast carcinoma: Prior studies have identified significantly increased risks with current (vs never) MHT use, with higher risks for ER+ than for ER- breast cancers when ER expression only was considered, [27] and for ER+/PR+ breast cancers but not ER-/PR-breast cancers when ER and PR expression was considered [8,28,29].